Obesity and obesity-related diseases are a major public health issue worldwide
With rising demand comes new challenges: capacity constraints, shifting regulatory expectations, and the unique requirements of emerging modalities, like cell and gene therapies, are reshaping the fill/finish landscape
This explainer will give you a brief overview of the issues and then summarize some recent publications the benefits and costs of drugs like semaglutide and tirzepatide
These include specific kidney conditions such as distal renal tubular acidosis and medullary sponge kidney, gout, hyperparathyroidism, inflammatory bowel disease (particularly Crohn's disease), and recurrent urinary tract infections
However, it is not currently FDA-approved for any condition and is expected to remain in the investigational phase for the near future